Foundayo (Orforglipron) Tablet

Description

What is Foundayo (Orforglipron)? 

Foundayo (Orforglipron), is a once-daily GLP-1 tablet made by Eli Lilly, the company behind Mounjaro. Foundayo was approved by the MHRA on August 10th 2026, making the UK the first country in Europe to approve it for weight management.

Oforglipron is a small-molecule, non-peptide compound, this allows it to survive the digestive process and be taken as a tablet rather than an injection. It acts on the GLP-1 receptor alone, Tirzepatide, the active ingredient in Mounjaro, works as a peptide injected once a week and acts on two hormone receptors, GLP-1 and GIP.  

Earlier oral GLP-1 attempts struggled with poor absorption when swallowed. Orforglipron’s structure gets around this. Unlike the Wegovy tablet, it can be taken at any time of day with or without food or water, something we cover in more detail below. 

How does Foundayo work? 

GLP-1 is a natural hormone released by your gut after eating. It sends signals between your gut, brain, and pancreas to suppress appetite, feel fuller for longer and keep blood sugar stable. Foundayo mimicks these signals. 

This means that Foundayo can support weight loss by reducing hunger, cravings (including “food noise”) and slowing how quickly food leaves the stomach so you feel full for longer. This can help you feel satisfied on smaller portions and support blood sugar control through insulin release when sugar levels are high. 

When combined with diet and exercise, these effects create a calorie deficit. These are the same core mechanisms that make Mounjaro and Wegovy effective; Mounjaro’s additional action on GIP receptors is thought to be part of why it tends to produce somewhat greater average weight loss in trials, which we look at below. 

How much weight can you lose on Foundayo? 

Two main Phase 3 trials have looked at this directly. 

• ATTAIN-1, in adults with obesity or individuals who were overweight but didn’t have type 2 diabetes, the study found participants on the highest dose lost an average of around 11% of their body weight over 72 weeks, compared with around 2% on placebo. 
• ATTAIN-2, in adults with obesity or individuals were overweight with type 2 diabetes, found an average loss of around 10.5% on the highest dose over the same period. 

For comparison, Mounjaro’s SURMOUNT-1 trial found an average loss of around 22.5% on its highest dose over 72 weeks, and the Wegovy tablet’s trial found around 13.6% over 64 weeks.

On the figures published so far, the injectable Mounjaro pen produces the greatest average weight loss of the three, with Foundayo currently showing the most modest results. That said, how an individual will respond to the medication can vary a great deal, and a daily tablet may suit some people better than a weekly injection regardless of the average numbers. 

Eligibility

The MHRA has set out that UK adults with a BMI of 30 or above, or a BMI of between 27 and 30, and at least one weight-related comorbidity will be allowed to use Foundayo.